My understanding is that the decision was made purely on the primary/functional endpoint (PUL 2.0 score).
i.e. They have clinical data BUT (to my knowledge) are awaiting lab data / haven't seen any of that at all.
That is to say that they wouldn't have seen data pertaining to lymphocyte counts, fat fractions, etc yet.
Funnily enough, I flicked an email off asking to confirm that they haven't seen any lab data earlier this arvo. I'd asked previously (20Dec) without response. I generally avoid pestering, but it's important for me to know that the comm's to date have been through a purely functional lens.
Ann: Notices received under s203D and s249D of Corporations Act, page-41
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.87M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.0¢ | 1.0¢ | $32.79K | 3.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 5659202 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 222168 | 2 |
View Market Depth
| Last trade - 14.17pm 23/06/2025 (20 minute delay) ? |
| PER (ASX) Chart |